Most Liquid Pharmaceuticals Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1TAK Takeda Pharmaceutical Co
233.74 B
 0.00 
 1.38 
 0.00 
2NVO Novo Nordisk AS
37.47 B
(0.11)
 3.85 
(0.44)
3MRK Merck Company
13.24 B
 0.05 
 1.89 
 0.10 
4BMY Bristol Myers Squibb
10.35 B
 0.00 
 1.92 
 0.00 
5NVS Novartis AG ADR
8.87 B
 0.09 
 1.30 
 0.12 
6SNY Sanofi ADR
6.9 B
(0.03)
 1.78 
(0.05)
7JNJ Johnson Johnson
5.37 B
 0.14 
 1.31 
 0.18 
8AZN AstraZeneca PLC ADR
4.52 B
 0.11 
 1.58 
 0.18 
9LLY Eli Lilly and
3.27 B
 0.03 
 1.92 
 0.05 
10GSK GlaxoSmithKline PLC ADR
2.75 B
 0.03 
 1.80 
 0.06 
11RDY Dr Reddys Laboratories
2.51 B
 0.05 
 1.49 
 0.08 
12TEVA Teva Pharma Industries
2.22 B
(0.08)
 2.43 
(0.20)
13ZTS Zoetis Inc
1.99 B
(0.09)
 1.57 
(0.15)
14RPRX Royalty Pharma Plc
1.47 B
 0.18 
 1.30 
 0.24 
15ARVN Arvinas
1.27 B
 0.07 
 3.08 
 0.23 
16CGC Canopy Growth Corp
1.23 B
(0.01)
 7.20 
(0.07)
17BHC Bausch Health Companies
1.18 B
 0.15 
 2.92 
 0.43 
18PFE Pfizer Inc
1.04 B
 0.07 
 1.47 
 0.11 
19CRON Cronos Group
944.89 M
 0.02 
 1.81 
 0.03 
20JAZZ Jazz Pharmaceuticals PLC
899.36 M
 0.15 
 1.65 
 0.24 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).